Home Ingredients Aniracetam (Ro 13-5057)
CognitiveMood & Mental HealthStress & Anxiety

Aniracetam (Ro 13-5057)

Synthetic — fat-soluble racetam derivative
Evidence Level
Limited
3 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Fat-soluble racetam developed by Roche (1970s), marketed in some European/Asian countries for cognitive impairment. Senin 1991 multicenter RCT in Alzheimer's disease showed positive psychobehavioral improvements vs placebo deterioration. AMPA receptor positive allosteric modulator with anxiolytic claims. Crosses BBB more readily than piracetam. Limited rigorous evidence; gray-zone status in US.

Studied Dose AD RCT: 1500 mg/day × 6 mo. STANDARD: 750-1500 mg/day in 2-3 doses with meals. NOOTROPIC: 750 mg 2-3×/day. Half-life ~1-2.5 hr (short). Italy/Japan Rx. NOT FDA-approved.
Active Compound Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone, Ro 13-5057, Draganon, Sarpul, Memodrin) — fat-soluble racetam, contrasting with water-soluble piracetam

Benefits

Mild Alzheimer's disease (Senin 1991 multicenter RCT)

double-blind randomized placebo-controlled multicenter trial in 109 elderly with mild-moderate probable Alzheimer's disease (NINCDS-ADRDA criteria) — 6 months of aniracetam (Ro 13-5057). Aniracetam group SIGNIFICANTLY DIFFERED from placebo by study end with statistically significant improvement in psychobehavioral parameters. Placebo group showed steady DETERIORATION. Excellent tolerability. Foundational trial for aniracetam in AD. Limited by 1991 diagnostic standards and modest sample size.

Supported by Trial 1

Mild cognitive deficit (Koliaki 2012 open-label)

Koliaki 2012 prospective open-label study in 276 patients with cognitive disorders comparing aniracetam monotherapy, ChEI monotherapy, combination, and no treatment over 12 months. Aniracetam monotherapy preserved neuropsychological parameters. Author conclusion: 'aniracetam... is a promising option for patients with cognitive deficit of mild severity.' Limited by open-label design (no blinding) but consistent with Senin 1991 directional findings.

Supported by Trial 2

Anxiolytic effects (preclinical/some clinical)

Animal studies show aniracetam has anxiolytic effects in elevated plus maze and conflict paradigms. Mechanism via AMPA receptor modulation and possibly indirect cholinergic effects. Some users report subjective anxiety reduction in nootropic context — limited rigorous human trials specifically for anxiety.

Supported by Trial 3, Trial 1

AMPA receptor positive allosteric modulation (mechanism)

Aniracetam acts as AMPA receptor positive allosteric modulator — enhances glutamate-mediated excitatory neurotransmission without direct agonism. Mechanism for proposed cognitive and mood effects. AMPA modulation considered theoretically promising for depression, cognition, and possibly schizophrenia. Aniracetam was prototype for AMPAkines drug class development.

Supported by Trial 2, Trial 3

Cholinergic and serotonergic effects (preclinical)

Aniracetam increases acetylcholine release in hippocampus and modulates 5-HT2A receptors in animal studies. Multi-modal neurotransmitter effects beyond AMPA. Mechanism for combined cognitive + mood effects observed clinically. Less specific than dedicated cholinesterase inhibitors but broader spectrum.

Supported by Trial 3, Trial 2

Mechanism of action

1

AMPA receptor positive allosteric modulation

Aniracetam is prototype AMPA receptor positive allosteric modulator (PAM) — slows AMPA receptor desensitization, prolonging excitatory glutamate transmission. Foundational compound that led to development of broader 'AMPAkines' drug class. Mechanism for cognitive enhancement via enhanced LTP (long-term potentiation) and synaptic plasticity.

2

Acetylcholine release enhancement

Increases ACh release in hippocampus and cortex (animal studies). Mechanism for memory and learning effects. Less specific than AChE inhibitors (donepezil) but broader downstream effects.

3

Serotonergic and dopaminergic modulation

Modulates 5-HT2A serotonin receptors and dopaminergic transmission in some preclinical models. Mechanism for proposed mood/anxiolytic effects beyond pure cognitive enhancement. Distinguishes aniracetam from piracetam in subjective effects profile.

4

Lipophilicity enhances BBB penetration

Fat-soluble structure (4-methoxybenzoyl group) crosses BBB more readily than water-soluble piracetam. Higher CNS concentrations achievable; faster onset. Trade-off: rapid hepatic metabolism to inactive metabolites (anisic acid, p-methoxybenzoic acid) requiring multiple daily doses.

Clinical trials

1
Senin 1991 — Aniracetam in Alzheimer's Multicenter RCT (Pivotal)
PubMed

Multicenter randomized double-blind placebo-controlled trial (Senin U, Abate G, Fieschi C, Gori G, Guala A, Marini G, Villardita C, Parnetti L 1991, Eur Neuropsychopharmacol 1(4):511-517, doi:10.1016/0924-977x(91)90004-e, PMID 1822317).

109 elderly patients with mild-moderate cognitive impairment fulfilling NINCDS-ADRDA criteria for probable Alzheimer's disease. 6 months treatment with aniracetam (Ro 13-5057) 1500 mg/day vs placebo. Bimonthly clinical, behavioral, and psychometric evaluations.

Aniracetam group SIGNIFICANTLY DIFFERED from placebo by study end. STATISTICALLY SIGNIFICANT improvement in psychobehavioral parameters with aniracetam vs baseline. PLACEBO group showed STEADY DETERIORATION. Tolerability EXCELLENT. Foundational positive RCT for aniracetam in AD. Limited by older NINCDS-ADRDA criteria, modest sample, single 1500 mg dose. Post-Senin trials less robustly positive overall.

2
Koliaki 2012 — Aniracetam Open-Label in Mixed Cognitive Disorders
PubMed

Prospective open-label comparative study (Koliaki CC, Messini C, Tsolaki M 2012, CNS Neurosci Ther 18(4):302-312, doi:10.1111/j.1755-5949.2010.00244.x, PMID 22070796).

276 patients (mean age 71±8 years, 95 males) with cognitive disorders categorized into 4 groups: no treatment (n=75), aniracetam monotherapy (n=58), ChEI monotherapy (n=68), combined treatment (n=68). Followed 12 months.

Aniracetam monotherapy PRESERVED ALL NEUROPSYCHOLOGICAL PARAMETERS for at least 12 months. Combined treatment with ChEI showed best outcomes. Authors concluded aniracetam is 'promising option for patients with cognitive deficit of mild severity.' LIMITED BY: open-label design (no blinding, no placebo), self-selection effects, observational design. Hypothesis-generating rather than confirmatory. Consistent with Senin 1991 direction.

3
Lee 2024 — Aniracetam Aβ Plaques Model Review
PubMed

Mechanistic review (Lee J, Sands ZA, Biggin PC, et al. 2024, Brain Sci 14, doi: review). PMC11091568.

Comprehensive mechanistic review of aniracetam's effects on Alzheimer's pathology — particularly amyloid-β plaque accumulation prevention.

Aniracetam shows preclinical evidence for AMPA-mediated synaptic preservation and reduced Aβ accumulation. Authors propose evidence-based model for aniracetam in AD prevention via AMPA receptor enhancement, BDNF release stimulation, and reduced excitotoxic damage. Mechanistic foundation supports potential preventive role; clinical translation still incomplete. Demonstrates ongoing scientific interest in aniracetam mechanisms despite limited definitive RCT base.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; excellent tolerability in Senin 1991.
Headache (less common than piracetam).
Anxiety, restlessness in some users.
GI upset (nausea, abdominal discomfort).
Insomnia if taken late in day (stimulating profile).
Pregnancy/lactation: avoid.
Long-term safety beyond 12 months: moderate data.

Important Drug interactions

Cholinergic medications: theoretical additive effects.
Anticoagulants: theoretical mild antiplatelet activity (less than piracetam).
Stimulants: theoretical additive CNS activation.
Most medications: compatible at typical doses.
Hepatic metabolism (CYP450) — theoretical interactions but limited clinical data.

More Cognitive Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Frequently asked questions about Aniracetam (Ro 13-5057)

What is Aniracetam (Ro 13-5057)?

Fat-soluble racetam developed by Roche (1970s), marketed in some European/Asian countries for cognitive impairment.

What does Aniracetam (Ro 13-5057) do?

Aniracetam is prototype AMPA receptor positive allosteric modulator (PAM) — slows AMPA receptor desensitization, prolonging excitatory glutamate transmission. Foundational compound that led to development of broader 'AMPAkines' drug class. In clinical research, Aniracetam (Ro 13-5057) has been studied for mild alzheimer's disease (senin 1991 multicenter rct), mild cognitive deficit (koliaki 2012 open-label), anxiolytic effects (preclinical/some clinical).

Who should take Aniracetam (Ro 13-5057)?

Aniracetam (Ro 13-5057) may be most relevant for people interested in cognitive, mood & mental health, stress & anxiety. It has been clinically studied for mild alzheimer's disease (senin 1991 multicenter rct), mild cognitive deficit (koliaki 2012 open-label), anxiolytic effects (preclinical/some clinical). As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Aniracetam (Ro 13-5057) take to work?

In clinical trials, effects typically appear over 12+ months of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Aniracetam (Ro 13-5057)?

For cognitive goals, Aniracetam (Ro 13-5057) is typically taken in the morning with breakfast for sustained daytime effects. Avoid late-day dosing if it affects your sleep. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Aniracetam (Ro 13-5057) worth taking?

Aniracetam (Ro 13-5057) has limited clinical evidence (Evidence Level 2/5 on NutraSmarts) — preliminary research suggests potential benefit, but more rigorous trials are needed. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Aniracetam (Ro 13-5057) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Aniracetam (Ro 13-5057)?

The clinically studied dose for Aniracetam (Ro 13-5057) is AD RCT: 1500 mg/day × 6 mo. STANDARD: 750-1500 mg/day in 2-3 doses with meals. NOOTROPIC: 750 mg 2-3×/day. Half-life ~1-2.5 hr (short). Italy/Japan Rx. NOT FDA-approved.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Aniracetam (Ro 13-5057) used for?

Aniracetam (Ro 13-5057) is studied for mild alzheimer's disease (senin 1991 multicenter rct), mild cognitive deficit (koliaki 2012 open-label), anxiolytic effects (preclinical/some clinical). double-blind randomized placebo-controlled multicenter trial in 109 elderly with mild-moderate probable Alzheimer's disease (NINCDS-ADRDA criteria) — 6 months of aniracetam (Ro 13-5057).